Viriyanata Wijaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Viriyanata Wijaya has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Lucie Cahlíková
Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic
2 shared publications - Rudolf Vrabec
Charles University
2 shared publications - Abdullah Al Mamun
ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
1 shared publication - Aneta Ritomská
Secondary Metabolites of Plants as Potential Drugs Research Group, Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
1 shared publication Anisa Dwi Aryani
Universitas Mulawarman
1 shared publication- Anna Hošťálková
ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 21 June 2026
- Published by Asosiasi Pengelola Publikasi Ilmiah Perguruan Tinggi PGRI in Archive: Jurnal Pengabdian Kepada Masyarakat
- Vol. 6 (1) , 73-80
Edukasi Penggunaan Obat pada Remaja di Sekolah Menengah Pertama Negeri 2 Samarinda
Latar Belakang: Penggunaan obat yang kurang tepat akibat kurangnya pemahaman mengenai proses mendapatkan, menggunakan, menyimpan dan membuang obat dengan benar masih menjadi permasalahan yang dapat berpengaruh terhadap keberhasilan terapi dan keamanan pasien. Tujuan: DAGUSIBU (Dapatkan, Gunakan, Simpan, dan Buang Obat dengan Benar) merupakan program pengajaran yang bertujuan untuk peningkatkan pengetahuan masyarakat mengenai manajemen obat yang tepat, khususnya pada remaja di SMP Negeri 2 Samarinda. Metode: Kegiatan dilaksanakan pada siswa kelas VIII dengan metode kuantitatif one group pre-test dan post-test design. Evaluasi diimplementasikan dengan pretest dan posttest guna mengukur tingkat pengetahuan peserta sebelum dan sesudah penyuluhan. Hasil: Adanya peningkatan pemahaman siswa setelah mendapatkan materi sebesar 9,76%. Persentase nilai pretest yang diperoleh sebelum penyuluhan sebesar 88,94%, sedangkan persentase nilai posttest setelah penyuluhan meningkat menjadi 98,7%. Kesimpulan: Peningkatan tersebut menunjukkan bahwa penyuluhan DAGUSIBU efektif dalam peningkatkan pengetahuan siswa.
- 21 June 2026
- Published by Asosiasi Pengelola Publikasi Ilmiah Perguruan Tinggi PGRI in Archive: Jurnal Pengabdian Kepada Masyarakat
- Vol. 6 (1) , 73-80
Open AccessEdukasi Penggunaan Obat pada Remaja di Sekolah Menengah Pertama Negeri 2 Samarinda
Latar Belakang: Penggunaan obat yang kurang tepat akibat kurangnya pemahaman mengenai proses mendapatkan, menggunakan, menyimpan dan membuang obat dengan benar masih menjadi permasalahan yang dapat berpengaruh terhadap keberhasilan terapi dan keamanan pasien. Tujuan: DAGUSIBU (Dapatkan, Gunakan, Simpan, dan Buang Obat dengan Benar) merupakan program pengajaran yang bertujuan untuk peningkatkan pengetahuan masyarakat mengenai manajemen obat yang tepat, khususnya pada remaja di SMP Negeri 2 Samarinda. Metode: Kegiatan dilaksanakan pada siswa kelas VIII dengan metode kuantitatif one group pre-test dan post-test design. Evaluasi diimplementasikan dengan pretest dan posttest guna mengukur tingkat pengetahuan peserta sebelum dan sesudah penyuluhan. Hasil: Adanya peningkatan pemahaman siswa setelah mendapatkan materi sebesar 9,76%. Persentase nilai pretest yang diperoleh sebelum penyuluhan sebesar 88,94%, sedangkan persentase nilai posttest setelah penyuluhan meningkat menjadi 98,7%. Kesimpulan: Peningkatan tersebut menunjukkan bahwa penyuluhan DAGUSIBU efektif dalam peningkatkan pengetahuan siswa.
- Open Access
- 17 June 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (6) , 844
Alkaloids of Dicranostigma franchetianum (Papaveraceae) and Berberine Derivatives as a New Class of Antimycobacterial Agents
Tuberculosis (TB) is a widespread infectious disease caused by Mycobacterium tuberculosis. The increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has created a need for new antiTB agents with new chemical scaffolds to combat the disease. Thus, the key question is: how to search for new antiTB and where to look for them? One of the possibilities is to search among natural products (NPs). In order to search for new antiTB drugs, the detailed phytochemical study of the whole Dicranostigma franchetianum plant was performed isolating wide spectrum of isoquinoline alkaloids (IAs). The chemical structures of the isolated alkaloids were determined by a combination of MS, HRMS, 1D, and 2D NMR techniques, and by comparison with literature data. Alkaloids were screened against Mycobacterium tuberculosis H37Ra and four other mycobacterial strains (M. aurum, M. avium, M. kansasii, and M. smegmatis). Alkaloids 3 and 5 showed moderate antimycobacterial activity against all tested strains (MICs 15.625–31.25 µg/mL). Furthermore, ten semisynthetic berberine (16a–16k) derivatives were developed and tested for antimycobacterial activity. In general, the derivatization of berberine was connected with a significant increase in antimycobacterial activity against all tested strains (MICs 0.39–7.81 μg/mL). Two derivatives (16e, 16k) were identified as compounds with micromolar MICs against M. tuberculosis H37Ra (MIC 2.96 and 2.78 µM). All compounds were also evaluated for their in vitro hepatotoxicity on a hepatocellular carcinoma cell line (HepG2), exerting lower cytotoxicity profile than their MIC values, thereby potentially reaching an effective concentration without revealing toxic side effects.
- 17 June 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (6) , 844
Open AccessAlkaloids of Dicranostigma franchetianum (Papaveraceae) and Berberine Derivatives as a New Class of Antimycobacterial Agents
Tuberculosis (TB) is a widespread infectious disease caused by Mycobacterium tuberculosis. The increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has created a need for new antiTB agents with new chemical scaffolds to combat the disease. Thus, the key question is: how to search for new antiTB and where to look for them? One of the possibilities is to search among natural products (NPs). In order to search for new antiTB drugs, the detailed phytochemical study of the whole Dicranostigma franchetianum plant was performed isolating wide spectrum of isoquinoline alkaloids (IAs). The chemical structures of the isolated alkaloids were determined by a combination of MS, HRMS, 1D, and 2D NMR techniques, and by comparison with literature data. Alkaloids were screened against Mycobacterium tuberculosis H37Ra and four other mycobacterial strains (M. aurum, M. avium, M. kansasii, and M. smegmatis). Alkaloids 3 and 5 showed moderate antimycobacterial activity against all tested strains (MICs 15.625–31.25 µg/mL). Furthermore, ten semisynthetic berberine (16a–16k) derivatives were developed and tested for antimycobacterial activity. In general, the derivatization of berberine was connected with a significant increase in antimycobacterial activity against all tested strains (MICs 0.39–7.81 μg/mL). Two derivatives (16e, 16k) were identified as compounds with micromolar MICs against M. tuberculosis H37Ra (MIC 2.96 and 2.78 µM). All compounds were also evaluated for their in vitro hepatotoxicity on a hepatocellular carcinoma cell line (HepG2), exerting lower cytotoxicity profile than their MIC values, thereby potentially reaching an effective concentration without revealing toxic side effects.
- Open Access
Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive age-related neurodegenerative disease recognized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be promising candidates for use in the treatment of AD. Since the introduction of galanthamine as an antidementia drug in 2001, Amaryllidaceae alkaloids (AAs) and further isoquinoline alkaloids (IAs) have been one of the most studied groups of alkaloids. In the last few years, several compounds of new structure types have been isolated and evaluated for their biological activity connected with AD. The present review aims to comprehensively summarize recent progress on AAs and IAs since 2010 up to June 2021 as potential drugs for the treatment of AD.
Open AccessRecent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive age-related neurodegenerative disease recognized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be promising candidates for use in the treatment of AD. Since the introduction of galanthamine as an antidementia drug in 2001, Amaryllidaceae alkaloids (AAs) and further isoquinoline alkaloids (IAs) have been one of the most studied groups of alkaloids. In the last few years, several compounds of new structure types have been isolated and evaluated for their biological activity connected with AD. The present review aims to comprehensively summarize recent progress on AAs and IAs since 2010 up to June 2021 as potential drugs for the treatment of AD.